Comparison · NCT00619359-28df9062
Fosaprepitant vs Aprepitant: A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin).
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Fosaprepitant vs Aprepitant: A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin). Trial comparisons, record NCT00619359-28df9062. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00619359-28df9062
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.743 | 0.717 | 0.768 | wilson | |
| Risk in group 2 | 0.742 | 0.716 | 0.767 | wilson | |
| Risk difference, group 1 minus group 2 | 0.000942 | -0.0353 | 0.0371 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.954 | 1.05 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.831 | 1.21 | log | |
| Number needed to treat, for one more participant with the outcome on Fosaprepitant than on Aprepitant | 1,060 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Fosaprepitant | Fosaprepitant dimeglumine 150 mg IV, ondansetron 32 mg IV, and dexamethasone 12 mg by mouth (PO) on Day 1, dexamethasone 8 mg PO on Day 2, and dexamethasone 16 mg PO on Days 3 and 4. | 822 | 1,106 | OG000 |
| Group 2 | Aprepitant | Aprepitant 125 mg by mouth (PO), ondansetron 32 mg IV, and dexamethasone 12 mg PO on Day 1, aprepitant 80 mg PO and dexamethasone 8 mg PO on Days 2 and 3, dexamethasone 8 mg PO on Day 4. | 841 | 1,133 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin).
- Description
- The number of patients who reported No Vomiting and No Use of Rescue Therapy in the 25 to 120 hours following initiation of cisplatin chemotherapy.
- Time frame
- Delayed phase (25 to 120 hours following initiation of cisplatin).
- Population
FAS (Full Analysis Set) patient population was used for all efficacy evaluations and included patients who: 1) received at least one dose of study therapy, 2) received cisplatin chemotherapy, and 3) had at least one post-treatment efficacy assessment. 1 patient (aprepitant group) had no delayed phase data, and was not included in this analysis.
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
- NCT number
- NCT00619359
- Phases
- PHASE3
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV)
- Interventions
- Comparator: fosaprepitant dimeglumine, Comparator: Aprepitant, Dexamethasone, Dexamethasone, Ondansetron
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2010-02-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00619359?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00619359-28df9062